SEC Form 4 · accession 0001140361-17-010367
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
V Bryan Lawlis
Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 2, 2017 · 6:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 1, 2017 | M | 7,500 | $17.33 | A | 21,360 | D | |
| Common StockF1,F2 | Mar 1, 2017 | S | 7,500 | $95.00 | D | 13,860 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Common StockF1,F4,F3 | $17.33 | Mar 1, 2017 | M | 7,500 | D | Dec 7, 2007 | Jun 6, 2017 | Common Stock | 7,500 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016.
- F2All shares were sold at the same price.
- F3Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th day of every month thereafter
- F4Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction.